bioAffinity Technologies/$BIAF
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About bioAffinity Technologies
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
Ticker
$BIAF
Sector
Primary listing
Employees
57
Headquarters
Website
BIAF Metrics
BasicAdvanced
$6.2m
-
-$5.86
-1.33
-
Price and volume
Market cap
$6.2m
Beta
-1.33
52-week high
$7.29
52-week low
$0.69
Average daily volume
208k
Financial strength
Current ratio
1.363
Quick ratio
1.188
Long term debt to equity
30.013
Total debt to equity
37.761
Interest coverage (TTM)
-265.14%
Profitability
EBITDA (TTM)
-11.086
Gross margin (TTM)
33.08%
Net profit margin (TTM)
-280.57%
Operating margin (TTM)
-204.28%
Effective tax rate (TTM)
-0.22%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-107.12%
Return on equity (TTM)
-622.65%
Valuation
Price to revenue (TTM)
0.656
Price to book
1.68
Price to tangible book (TTM)
3.96
Price to free cash flow (TTM)
-0.34
Free cash flow yield (TTM)
-294.46%
Free cash flow per share (TTM)
-4.034
Growth
Revenue change (TTM)
-35.75%
Earnings per share change (TTM)
-72.49%
3-year revenue growth (CAGR)
896.25%
3-year earnings per share growth (CAGR)
-47.93%
BIAF News
AllArticlesVideos
bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
Business Wire·3 hours ago
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies' Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
Business Wire·2 weeks ago
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs